Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 34, 2023 - Issue 1
Submit an article Journal homepage
1,192
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

Pemphigus foliaceus treated with minocycline monotherapy or low-dose prednisolone combination therapy

Birao Fana Department of Dermatology, Peking University First Hospital, Beijing, P. R. China;b National Clinical Research Center for Skin and Immune Diseases, Beijing, P. R. China;c Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, P. R. ChinaView further author information
,
Xixue Chena Department of Dermatology, Peking University First Hospital, Beijing, P. R. China;b National Clinical Research Center for Skin and Immune Diseases, Beijing, P. R. China;c Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, P. R. ChinaView further author information
,
Xuejun Zhua Department of Dermatology, Peking University First Hospital, Beijing, P. R. China;b National Clinical Research Center for Skin and Immune Diseases, Beijing, P. R. China;c Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, P. R. ChinaView further author information
&
Mingyue Wanga Department of Dermatology, Peking University First Hospital, Beijing, P. R. China;b National Clinical Research Center for Skin and Immune Diseases, Beijing, P. R. China;c Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, P. R. ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-8317-3414View further author information
ORCID Icon
Article: 2113756 | Received 16 Jan 2022, Accepted 11 Aug 2022, Published online: 17 Oct 2022

References

  • Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. Lancet. 2019;394(10201):882–894.
  • Hertl M, Jedlickova H, Karpati S, et al. Pemphigus. S2 guideline for diagnosis and treatment-guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2015;29(3):405–414.
  • Boulard C, Duvert Lehembre S, Picard-Dahan C, et al. Calculation of cut-off values based on the autoimmune bullous skin disorder intensity score (ABSIS) and pemphigus disease area index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus. Br J Dermatol. 2016;175(1):142–149.
  • Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol. 2008;58(6):1043–1046.
  • Joly P, Roujeau JC, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346(5):321–327.
  • Garner SE, Eady A, Bennett C, et al. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev. 2012;2012:CD002086.
  • Rice JB, White AG, Scarpati LM, et al. Long-term systemic corticosteroid exposure: a systematic literature review. Clin Ther. 2017;39(11):2216–2229.
  • Fivenson DP, Breneman DL, Rosen GB, et al. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol. 1994;130(6):753–758.
  • Chaffins M, Collison D, Fivenson D. Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: a review of 13 cases. J Am Acad Dermatol. 1993;28(6):998–1000.
  • Alpsoy E, Yilmaz E, Basaran E, et al. Is the combination of tetracycline and nicotinamide alone effective in pemphigus? Arch Dermatol. 1995;131(11):1339–1340.
  • McCarty M, Fivenson D. Two decades of using the combination of tetracycline derivatives and niacinamide as steroid-sparing agents in the management of pemphigus: defining a niche for these low toxicity agents. J Am Acad Dermatol. 2014;71(3):475–479.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.